Want to see KOD full AI Analyst Report?

Kodiak Sciences (KOD) Price & Analysis

573 Followers

KOD Stock Chart & Stats

$39.33

$0.50(1.21%)

At close: Jul 27 4:00 PM EDT

$39.33

$0.50(1.21%)

Day’s Range― - ―

52-Week Range$15.83 - $104.00

Previous Close$42.01

Volume464.83K

Average Volume (3M)2.92M

Market Cap

$5.84B

Enterprise Value$2.47B

Total Cash (Recent Filing)$125.90M

Total Debt (Recent Filing)$95.70M

Price to Earnings (P/E)―

Beta2.15

Next Earnings

Nov 12, 2026

EPS Estimate

-1.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-4.19

Shares Outstanding62,849,457

10 Day Avg. Volume1,488,847

30 Day Avg. Volume2,920,471

Financial Highlights & Ratios

PEG Ratio-0.22

Price to Book (P/B)9.45

Price to Sales (P/S)0.00

P/FCF Ratio-10.90

Enterprise Value/Market Cap0.42

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.54

Forecast

1Y Price Target

$121.20

Price Target Upside208.16% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

EPS Forecast (FY)-4.08

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Phase 3 ValidationPositive Phase 3 results materially reduce clinical development uncertainty and support the potential for regulatory approval. Non-inferior vision outcomes against aflibercept provide a credible efficacy foundation for future commercialization in a large retinal disease market.

Long-acting Treatment PotentialSix-month dosing durability could differentiate Kodiak’s therapies by reducing injection frequency for patients and treatment burden for providers. If sustained through regulatory review and launch, this feature may strengthen adoption and support a durable competitive position.

Improved Debt PositionThe substantial year-over-year debt reduction lowers leverage and may reduce financing pressure relative to the prior year. A less debt-burdened balance sheet gives management more flexibility to prioritize clinical development and prepare the pipeline for commercialization.

Bears Say

Pre-revenue Business ModelKodiak has not yet established recurring product revenue, so its ability to fund operations depends on external financing, partnerships, or successful commercialization. This leaves the business exposed to execution and approval outcomes before a self-sustaining revenue base emerges.

Sustained Cash BurnPersistent negative cash generation means Kodiak must continue consuming capital to advance its programs and operate the business. Ongoing burn can force additional financing or strategic transactions, potentially limiting flexibility and increasing dilution or funding risk.

Shrinking Equity And Large LossesSharp equity compression alongside substantial losses weakens the company’s financial cushion and reduces capacity to absorb delays or higher development costs. Until commercialization improves earnings, this combination keeps balance-sheet resilience and long-term funding flexibility constrained.

Kodiak Sciences News

Kodiak Sciences files automatic mixed securities shelf

17:20 EDT Kodiak Sciences (KOD) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

2d ago

KOD

Kodiak Sciences put volume heavy and directionally bearish

Bearish flow noted in Kodiak Sciences (KOD) with 5,384 puts trading, or 1.7x expected. Most active are Oct-26...

8d ago

KOD

Kodiak Sciences price target raised to $126 from $96 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kodiak Sciences (KOD) to $126 from $96 and keeps a...

11d ago

KOD

Short Report: Kodiak Sciences short interest at record high

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

18d ago

KOD

JPMorgan healthcare analysts hold an analyst/industry conference call

Healthcare Analysts discuss the evolving landscape in Retinal diseases (relevant companies KOD REGN ANNX EYPT) on an Analyst/Industry...

20d ago

KOD

ANNX

Kodiak Sciences price target raised to $103 from $36 at Goldman Sachs

Goldman Sachs analyst Andrea Newkirk raised the firm’s price target on Kodiak Sciences (KOD) to $103 from $36...

23d ago

KOD

Kodiak Sciences price target raised to $120 from $80 at UBS

UBS analyst Michael Yee raised the firm’s price target on Kodiak Sciences (KOD) to $120 from $80 and...

24d ago

KOD

Kodiak Sciences price target raised to $112 from $56 at Jefferies

Jefferies raised the firm’s price target on Kodiak Sciences (KOD) to $112 from $56 and keeps a Buy...

24d ago

KOD

Kodiak Sciences price target raised to $145 from $85 at LifeSci Capital

LifeSci Capital raised the firm’s price target on Kodiak Sciences (KOD) to $145 from $85 and keeps an...

24d ago

KOD

REGN

Kodiak Sciences rises 161.9%

Kodiak Sciences (KOD) is up 161.9%, or $52.36 to $84.71. Published first on TheFly – the ultimate source...

24d ago

KOD

Patrick Dolezal Lifts Kodiak Sciences Price Target to $145 on Strong Zenkuda DAYBREAK Data and Enhanced Durability Profile

In a report released today, Patrick Dolezal from LifeSci Capital maintained a Buy rating on Kodiak Sciences, with...

24d ago

KOD

Kodiak Sciences posts positive Phase 3 DAYBREAK eye results

Kodiak Sciences ( ($KOD) ) has provided an update. On September 28, 2026, Kodiak Sciences reported that its...

24d ago

KOD

Analyst Maintains Buy on Kodiak Sciences, Reaffirming Unchanged $58 Price Target Ahead of Key Phase 3 Readouts

Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Kodiak Sciences. The associated price target...

1M ago

KOD

Kodiak Sciences Advances ALTO Phase 3 Trial In Diabetic Eye Disease

Kodiak Sciences ($KOD) announced an update on their ongoing clinical study. Kodiak Sciences Inc. (KOD) is running a...

2M ago

KOD

KOD FAQ

What was Kodiak Sciences Inc’s price range in the past 12 months?

Kodiak Sciences Inc lowest stock price was $15.83 and its highest was $104.00 in the past 12 months.

What is Kodiak Sciences Inc’s market cap?

Kodiak Sciences Inc’s market cap is $5.84B.

When is Kodiak Sciences Inc’s upcoming earnings report date?

Kodiak Sciences Inc’s upcoming earnings report date is Nov 12, 2026 which is in 20 days.

How were Kodiak Sciences Inc’s earnings last quarter?

Kodiak Sciences Inc released its earnings results on Aug 13, 2026. The company reported -$1.05 earnings per share for the quarter, missing the consensus estimate of -$0.956 by -$0.094.

Is Kodiak Sciences Inc overvalued?

According to Wall Street analysts Kodiak Sciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kodiak Sciences Inc pay dividends?

Kodiak Sciences Inc does not currently pay dividends.

What is Kodiak Sciences Inc’s EPS estimate?

Kodiak Sciences Inc’s EPS estimate is -1.06.

How many shares outstanding does Kodiak Sciences Inc have?

Kodiak Sciences Inc has 62,849,457 shares outstanding.

What happened to Kodiak Sciences Inc’s price movement after its last earnings report?

Kodiak Sciences Inc reported an EPS of -$1.05 in its last earnings report, missing expectations of -$0.956. Following the earnings report the stock price went up 3.427%.

Which hedge fund is a major shareholder of Kodiak Sciences Inc?

Currently, no hedge funds are holding shares in KOD

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Kodiak Sciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-273.23%

Trailing 12-Months

Asset Growth

0.03%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Kodiak Sciences Inc

Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.

Kodiak Sciences (KOD) Earnings & Revenues

Historic Earnings Reports

KOD Stock 12 Month Forecast

Average Price Target

$121.20

▲(208.16% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"$14","47":"$47","80":"$80","113":"$113","146":"$146"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":145,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$145.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":121.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$121.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":103,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$103.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,47,80,113,146],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.46,102.03999999999999,105.61999999999999,109.19999999999999,112.78,116.36,119.94,123.52,127.1,130.68,134.26,137.84,141.42000000000002,{"y":145,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.46,100.20923076923076,101.95846153846153,103.7076923076923,105.45692307692308,107.20615384615384,108.95538461538462,110.70461538461538,112.45384615384616,114.20307692307692,115.9523076923077,117.70153846153846,119.45076923076923,{"y":121.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,98.46,98.80923076923077,99.15846153846154,99.50769230769231,99.85692307692307,100.20615384615384,100.55538461538461,100.90461538461538,101.25384615384615,101.60307692307693,101.95230769230768,102.30153846153846,102.65076923076923,{"y":103,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":15.76,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.125,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.96,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.36,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.81,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.96,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.91,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.24,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.58,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.06,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.46,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >